Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens

Clin Colorectal Cancer. 2011 Sep;10(3):203-6. doi: 10.1016/j.clcc.2011.03.015. Epub 2011 Apr 28.

Authors

Jennifer Saam¹, Gregory C Critchfield, Stephanie A Hamilton, Benjamin B Roa, Richard J Wenstrup, Rajesh R Kaldate

Affiliation

¹ Myriad Genetic Laboratories, Inc, Salt Lake City, UT, USA.

PMID: 21855044
DOI: 10.1016/j.clcc.2011.03.015

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Area Under Curve
Bevacizumab
Body Surface Area*
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Chemotherapy, Adjuvant
Clinical Trials as Topic
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / pathology
Fluorouracil / administration & dosage
Humans
Irinotecan
Leucovorin / administration & dosage
Organoplatinum Compounds / administration & dosage
Oxaliplatin
Precision Medicine*

Substances

Antibodies, Monoclonal, Humanized
Organoplatinum Compounds
Oxaliplatin
Bevacizumab
Irinotecan
Leucovorin
Fluorouracil
Camptothecin